Republicans tear into Pentagon's Ukraine weapons freeze
Republican Rep. Brian Fitzpatrick, co-chair of the Congressional Ukraine Caucus, said he would be 'aggressively looking into this matter' following the White House's acknowledgment that the Pentagon froze deliveries of critical air defense weapons due to concerns over shrinking U.S. stockpiles.
'We must build up our own defense industrial base here in the U.S. while simultaneously providing the needed assistance to our allies who are defending their freedom from a brutal invading dictator,' the Pennsylvania representative said in a post on X. 'To not do both is unacceptable.'
Fitzpatrick later requested an emergency briefing from the White House and Pentagon.
Lawmakers of varying political stripes called the holdup of weapons approved during the Biden administration a breach of Trump's renewed commitment to Kyiv at last week's NATO summit, where the president floated selling Patriot air defense systems to Ukraine. POLITICO first reported the news on Tuesday, and since then, Kyiv has summoned a U.S. diplomat to explain the hold.
Rep. Michael McCaul (R-Texas) said he is probing 'very intensely' whether the Pentagon's freeze is a breach of Ukraine aid legislation that Congress passed in 2024. He also argued the pause is coming 'at the wrong time,' weakening Trump's efforts to pressure Russian President Vladimir Putin to negotiate a peace deal with Ukraine.
'If you want to get him to the negotiating table in good faith, you have to put leverage and pressure on him, and that would be Lindsey Graham's economic sanctions and the flow of weapons,' McCaul said. 'If you take the flow of weapons out, yeah, then you're not, you don't have the leverage over Putin to negotiate.'
Democrats — who during Trump's first term pressed for his impeachment over holding up money to arm Ukraine to secure information on the dealings of his main Democratic rival, Joe Biden, and his family — assailed the aid holdup.
But some top lawmakers weren't ready to pin the blame on Trump himself. Rather, they singled out senior Pentagon officials who have been skeptics of further aid to Ukraine.
Sen. Jeanne Shaheen (D-N.H.), the top Democrat on the Senate Foreign Relations Committee, called out Defense Secretary Pete Hegseth and Pentagon policy chief Elbridge Colby, a longtime proponent of shifting U.S. military resources away from Ukraine in order to beef up Taiwan's defenses.
She argued the pause undermines Trump's commitments at NATO and urged Secretary of State Marco Rubio, who is simultaneously serving as White House national security adviser, to enforce a strategy.
"The Trump administration's mixed messaging is undermining its own agenda to bring Putin to the negotiating table, and this move under Secretary Hegesth's leadership will only make a just and lasting peace harder to obtain," Shaheen said in a statement. "Now is not the time for rogue actors undermining our national security interests.'
Sen. Richard Blumenthal (D-Conn.), a senior Senate Armed Services Committee member, called the rationale behind the freeze 'fallacious and maybe even disingenuous.' He said he and colleagues in both parties were surprised by the news — and that Ukrainians will suffer.
'They're going to lose more lives, more people will be maimed and injured — more homes, hospitals, schools will be destroyed,' he said in an interview. 'The Russians … are not even making a pretense of going after military targets.'
Other top Republicans were less troubled by reports of the stalled weapons shipments. Rep. Ken Calvert (R-Calif.), who chairs the panel that controls much of the Pentagon budget, said he still needed to examine what munitions Ukraine has in its inventory, but suggested supply concerns might be warranted.
'I think part of it is the supply. So we've been running through a lot of Standard Missiles, the whole Patriot system,' Calvert said. 'The other part of it is that the Europeans are beginning to pick up the slack.
'I don't know what they have in inventory right now, the Ukrainians. I'll find that out,' he said.
House Armed Services Chair Mike Rogers (R-Ala.) said he hadn't been informed of a pause on munitions shipments, but he noted the Trump administration has 'done it several times.'
'I don't know that he paused it for any purpose other than something regular that they do,' Rogers said of Trump. 'I don't have any reason to be upset about it until I learn more.'
Trump's allies on Capitol Hill defended the move. House Foreign Affairs Chair Brian Mast (R-Fla.) said he hadn't heard of a specific delay but said there's a 'constant check and balance' in terms of what gets sent to Ukraine.
'You always want to make sure that your supply line is smooth, but if you're constantly making the checks, then it keeps them constantly vigilant,' Mast said. 'If you weren't constantly doing this, then all of a sudden, they're going to get themselves wrapped around the axle when you really do check it. So I think in the end, it makes for a smoother system.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to invest in now. On July 22, Morgan Stanley analyst Sean Laaman maintained a Buy rating on Exelixis, Inc. (NASDAQ:EXEL) and set a price target of $48.00. A team of scientists in lab coats surrounded by pharmaceuticals and medical equipment, researching a life-saving oncology-focused biotechnology. The analyst reasoned that Exelixis, Inc. (NASDAQ:EXEL) recently updated its 2025 revenue guidance, increasing it to a $2.25-2.35 billion range after the higher-than-expected sales of Cabo. He attributed this optimistic outlook to the persistent demand growth and new patient starts in first-line renal cell carcinoma (1L RCC). Laaman also stated that Exelixis, Inc. (NASDAQ:EXEL) reported that it may update its guidance further as the NET launch progresses and additional revenue opportunities become clearer. Exelixis, Inc. (NASDAQ:EXEL) discovers, develops, and commercializes new medicines for difficult-to-treat cancers. Its product portfolio includes cabometyx, cometriq, and cotellic. While we acknowledge the potential of EXEL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
The Open Group Launches The Open Group Open Digital Transformation™ Forum
Standards body aims to spur faster, more effective transformation initiatives SAN FRANCISCO, July 28, 2025--(BUSINESS WIRE)--The Open Group, the vendor-neutral technology consortium, has today announced the formation of The Open Group Open Digital Transformation™ Forum (ODXF). This new initiative will support enterprise Digital Transformation by developing and popularizing pragmatic, open standards in this increasingly valuable and challenging space. By establishing clear guidelines for Digital Transformation initiatives and enabling cross-industry collaboration to share insights and best practices, ODXF aims to ensure that a greater share of Digital Transformation investment globally delivers effective returns on investment and measurably positive impacts on cultural, workforce, and technological changes. "The vast majority of enterprises today are engaged in Digital Transformation initiatives, with significant global spend in Digital Transformation," commented Rashed Al-Yami, Governing Board Member of The Open Group and Manager Digital Platforms & Architecture Design Division at Aramco. "By developing open standards through vendor-neutral collaboration, ODXF can influence the Digital Transformation agenda towards more rigorous and successful practices." Key focus areas for ODXF include developing standardized frameworks for Digital Transformation initiatives, ensuring consistency, and producing reference architectures which organizations can incorporate in order to make their own Digital Transformation journeys more agile and responsive. The Forum will also collaborate on establishing a body of knowledge, which incorporates a range of documents designed to help users operationalize the standard, as well as ultimately delivering a certification program for practitioners to demonstrate that they understand and can apply best-in-class approaches to Digital Transformation. "Digital Transformation is not a new term, but the emergence of a range of disruptive technologies, from AI to quantum computing, has made it more urgent than ever for businesses to find a clear guiding path towards proven approaches to this challenge," said Steve Nunn, President and CEO of The Open Group. "Our track record of bringing industry stakeholders together in a neutral, collaborative space means that The Open Group is well placed to add value to one of the world's major areas of investment." To learn more about The Open Group Open Digital Transformation Forum, please visit here. About The Open Group The Open Group is a global consortium that enables the achievement of business objectives through technology standards and open source initiatives by fostering a culture of collaboration, inclusivity, and mutual respect among our diverse group of 900+ memberships. Our Membership includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. View source version on Contacts Media contact Monika BoudovaHotwire for The Open GroupUKOpengroup@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio